{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:35:45Z","timestamp":1793223345219,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1038\/s41375-025-02705-4","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T09:04:37Z","timestamp":1754471077000},"page":"2432-2441","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A novel chimeric antigen receptor T-cell therapy targeting CD84 for the treatment of acute myeloid and T-cell lymphoblastic leukemias"],"prefix":"10.1038","volume":"39","author":[{"given":"Lorena","family":"P\u00e9rez-Amill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4069-9915","authenticated-orcid":false,"given":"Mercedes","family":"Armand-Ug\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2481-3295","authenticated-orcid":false,"given":"Maria","family":"Val-Casals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7286-9555","authenticated-orcid":false,"given":"Beatriz","family":"Mart\u00edn-Herreros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 R.","family":"\u00c1lamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1619-3990","authenticated-orcid":false,"given":"Sergio","family":"Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6794-6456","authenticated-orcid":false,"given":"Gerard","family":"Frigola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8350-1609","authenticated-orcid":false,"given":"Ane","family":"Altuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6376-0929","authenticated-orcid":false,"given":"Francesca","family":"Guijarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Minguela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6085-2745","authenticated-orcid":false,"given":"\u00c0lex","family":"Bataller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5728-2932","authenticated-orcid":false,"given":"Berta","family":"Casanovas-Albert\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2618-1116","authenticated-orcid":false,"given":"Mireia","family":"Uribe-Herranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5978-2578","authenticated-orcid":false,"given":"Manuel","family":"Guerreiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"S\u00e1nchez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00e9stor","family":"Tirado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2183-7443","authenticated-orcid":false,"given":"Tal\u00eda","family":"Velasco-Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Men\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montse","family":"Rovira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7486-8484","authenticated-orcid":false,"given":"Dolors","family":"Colomer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Azucena","family":"Gonz\u00e1lez-Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8056-648X","authenticated-orcid":false,"given":"Jordi","family":"Esteve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Urbano-Ispizua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3275-5593","authenticated-orcid":false,"given":"Pau","family":"Montesinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5157-4376","authenticated-orcid":false,"given":"Julio","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3064-1648","authenticated-orcid":false,"given":"Manel","family":"Juan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4593-6457","authenticated-orcid":false,"given":"Nela","family":"Klein-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"2705_CR1","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","volume":"38","author":"M Hong","year":"2020","unstructured":"Hong M, Clubb JD, Chen YY. Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell. 2020;38:473\u201388.","journal-title":"Cancer Cell"},{"key":"2705_CR2","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439\u201348.","journal-title":"N Engl J Med"},{"key":"2705_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019;20:31\u201342.","journal-title":"Lancet Oncol"},{"key":"2705_CR4","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","volume":"398","author":"BD Shah","year":"2021","unstructured":"Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398:491\u2013502.","journal-title":"Lancet"},{"key":"2705_CR5","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839\u201352.","journal-title":"Lancet"},{"key":"2705_CR6","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705\u201316.","journal-title":"N Engl J Med"},{"key":"2705_CR7","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398:314\u201324.","journal-title":"Lancet"},{"key":"2705_CR8","first-page":"325","volume":"11","author":"EN Oliva","year":"2021","unstructured":"Oliva EN, Ronnebaum SM, Zaidi O, Patel DA, Nehme SA, Chen C, et al. A systematic literature review of disease burden and clinical efficacy for patients with relapsed or refractory acute myeloid leukemia. Am J Blood Res. 2021;11:325\u201360.","journal-title":"Am J Blood Res"},{"key":"2705_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2020.00273","volume":"10","author":"B Fattizzo","year":"2020","unstructured":"Fattizzo B, Rosa J, Giannotta JA, Baldini L, Fracchiolla NS. The physiopathology of T-cell acute lymphoblastic leukemia: focus on molecular aspects. Front Oncol. 2020;10:1\u201311.","journal-title":"Front Oncol"},{"key":"2705_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2023.1260470","volume":"14","author":"L P\u00e9rez-Amill","year":"2023","unstructured":"P\u00e9rez-Amill L, Bataller \u00c0, Delgado J, Esteve J, Juan M, Klein-Gonz\u00e1lez N. Advancing CART therapy for acute myeloid leukemia: recent breakthroughs and strategies for future development. Front Immunol. 2023;14:1\u201322.","journal-title":"Front Immunol"},{"key":"2705_CR11","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1038\/leu.2015.52","volume":"29","author":"SS Kenderian","year":"2015","unstructured":"Kenderian SS, Ruella M, Shestova O, Klichinsky M, Aikawa V, Morrissette JJD, et al. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia. 2015;29:1637\u201347.","journal-title":"Leukemia"},{"key":"2705_CR12","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/mt.2014.164","volume":"23","author":"QS Wang","year":"2015","unstructured":"Wang QS, Wang Y, Lv HY, Han QW, Fan H, Guo B, et al. Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol Ther. 2015;23:184\u201391.","journal-title":"Mol Ther"},{"key":"2705_CR13","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","volume":"173","author":"MY Kim","year":"2018","unstructured":"Kim MY, Yu KR, Kenderian SS, Ruella M, Chen S, Shin TH, et al. Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T Cell immunotherapy for acute myeloid leukemia. Cell. 2018;173:1439\u201353.","journal-title":"Cell"},{"key":"2705_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-022-29668-9","volume":"13","author":"M Sugita","year":"2022","unstructured":"Sugita M, Galetto R, Zong H, Ewing-Crystal N, Trujillo-Alonso V, Mencia-Trinchant N, et al. Allogeneic TCR\u03b1\u03b2 deficient CAR T-cells targeting CD123 in acute myeloid leukemia. Nat Commun. 2022;13:1\u201311.","journal-title":"Nat Commun"},{"key":"2705_CR15","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1158\/1078-0432.CCR-20-4543","volume":"27","author":"H Zhang","year":"2021","unstructured":"Zhang H, Wang P, Li Z, He Y, Gan W, Jiang H. Anti-CLL1 chimeric antigen receptor T-cell therapy in children with relapsed\/refractory acute myeloid leukemia. Clin Cancer Res. 2021;27:3549\u201355.","journal-title":"Clin Cancer Res"},{"key":"2705_CR16","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.3390\/ijms18112259","volume":"18","author":"E Laborda","year":"2017","unstructured":"Laborda E, Mazagova M, Shao S, Wang X, Quirino H, Woods AK, et al. Development of a chimeric antigen receptor targeting c-type lectin-like molecule-1 for human acute myeloid leukemia. Int J Mol Sci. 2017;18:2259.","journal-title":"Int J Mol Sci"},{"key":"2705_CR17","doi-asserted-by":"publisher","first-page":"e000845","DOI":"10.1136\/jitc-2020-000845","volume":"8","author":"ML Baroni","year":"2020","unstructured":"Baroni ML, Sanchez Martinez D, Gutierrez Aguera F, Roca Ho H, Castella M, Zanetti SR, et al. 41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo. J Immunother Cancer. 2020;8:e000845.","journal-title":"J Immunother Cancer"},{"key":"2705_CR18","doi-asserted-by":"crossref","unstructured":"Fiorenza S, Turtle CJ. CAR-T cell therapy for acute myeloid leukemia: preclinical rationale, current clinical progress, and barriers to success. BioDrugs. 2021;35:281\u2013302.","DOI":"10.1007\/s40259-021-00477-8"},{"key":"2705_CR19","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","volume":"380","author":"N Pemmaraju","year":"2019","unstructured":"Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019;380:1628\u201337.","journal-title":"N Engl J Med"},{"key":"2705_CR20","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1182\/blood-2018-10-882944","volume":"133","author":"D S\u00e1nchez-Mart\u00ednez","year":"2019","unstructured":"S\u00e1nchez-Mart\u00ednez D, Baroni ML, Gutierrez-Ag\u00fcera F, Roca-Ho H, Blanch-Lombarte O, Gonz\u00e1lez-Garc\u00eda S, et al. Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia. Blood. 2019;133:2291\u2013304.","journal-title":"Blood"},{"key":"2705_CR21","doi-asserted-by":"crossref","unstructured":"Tirado N, Mansilla MJ, Mart\u00ednez-Moreno A, Alcain J, Garc\u00eda-Peydr\u00f3 M, Roca-Ho H, et al. CAR-T cells targeting CCR9 and CD1a for the treatment of T cell acute lymphoblastic leukemia. J Hematol Oncol. 2025;18:69.","DOI":"10.1186\/s13045-025-01715-0"},{"key":"2705_CR22","doi-asserted-by":"crossref","unstructured":"Pan J, Tan Y, Shan L, Seery S, Deng B, Ling Z, et al. Allogeneic CD5-specific CAR-T therapy for relapsed\/refractory T-ALL: a phase 1 trial. Nat Med. 2025;31:126\u2013136.","DOI":"10.1038\/s41591-024-03282-2"},{"key":"2705_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-023-00822-w","volume":"13","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Li C, Du M, Jiang H, Luo W, Tang L, et al. Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies. Blood Cancer J. 2023;13:1\u201310.","journal-title":"Blood Cancer J"},{"key":"2705_CR24","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1056\/NEJMoa2313812","volume":"390","author":"Y Hu","year":"2024","unstructured":"Hu Y, Zhang M, Yang T, Mo Z, Wei G, Jing R, et al. Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis. N Engl J Med. 2024;390:1467\u201380.","journal-title":"N Engl J Med"},{"key":"2705_CR25","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1182\/blood.V90.6.2398","volume":"90","author":"MA De La Fuente","year":"1997","unstructured":"De La Fuente MA, Pizcueta P, Nadal M, Bosch J, Engel P. CD84 Leukocyte antigen is a new member of the Ig superfamily. Blood. 1997;90:2398\u2013405.","journal-title":"Blood"},{"key":"2705_CR26","doi-asserted-by":"publisher","first-page":"3668","DOI":"10.4049\/jimmunol.167.7.3668","volume":"167","author":"M Martin","year":"2001","unstructured":"Martin M, Romero X, de la Fuente MA, Tovar V, Zapater N, Esplugues E, et al. CD84 functions as a homophilic adhesion molecule and enhances IFN-\u03b3 secretion: adhesion is mediated by Ig-like domain 1. J Immunol. 2001;167:3668\u201376.","journal-title":"J Immunol"},{"key":"2705_CR27","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.clim.2018.10.017","volume":"204","author":"M Cuenca","year":"2019","unstructured":"Cuenca M, Sintes J, L\u00e1nyi \u00c1, Engel P. CD84 cell surface signaling molecule: an emerging biomarker and target for cancer and autoimmune disorders. Clin Immunol. 2019;204:43\u20139.","journal-title":"Clin Immunol"},{"key":"2705_CR28","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1038\/onc.2013.31","volume":"33","author":"I Binsky-Ehrenreich","year":"2014","unstructured":"Binsky-Ehrenreich I, Marom A, Sobotta MC, Shvidel L, Berrebi A, Hazan-Halevy I, et al. CD84 is a survival receptor for CLL cells. Oncogene. 2014;33:1006\u201316.","journal-title":"Oncogene"},{"key":"2705_CR29","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/onc.2016.238","volume":"36","author":"A Marom","year":"2017","unstructured":"Marom A, Barak AF, Kramer MP, Lewinsky H, Binsky-Ehrenreich I, Cohen S, et al. CD84 mediates CLL-microenvironment interactions. Oncogene. 2017;36:628\u201338.","journal-title":"Oncogene"},{"key":"2705_CR30","first-page":"1","volume":"6","author":"H Lewinsky","year":"2021","unstructured":"Lewinsky H, Gunes EG, David K, Radomir L, Kramer MP, Pellegrino B, et al. CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma. JCI Insight. 2021;6:1\u201325.","journal-title":"JCI Insight"},{"key":"2705_CR31","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1182\/blood-2022-170300","volume":"140","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Park M, Murtadha M, Caserta E, Nguyen LXT, Singer M, et al. CD84 is a therapeutically targetable driver of leukemogenesis via disruption of energy supply in acute myeloid leukemia. Blood. 2022;140:89\u201390.","journal-title":"Blood"},{"key":"2705_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2014.00134","volume":"4","author":"RJ Orentas","year":"2014","unstructured":"Orentas RJ, Nordlund J, He J, Sindiri S, Mackall C, Fry TJ, et al. Bioinformatic description of immunotherapy targets for pediatric T-cell leukemia and the impact of normal gene sets used for comparison. Front Oncol. 2014;4:1\u201311.","journal-title":"Front Oncol"},{"key":"2705_CR33","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","volume":"45","author":"Z Tang","year":"2017","unstructured":"Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98\u2013102.","journal-title":"Nucleic Acids Res"},{"key":"2705_CR34","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.stem.2010.11.014","volume":"7","author":"Y Kikushige","year":"2010","unstructured":"Kikushige Y, Shima T, Takayanagi SI, Urata S, Miyamoto T, Iwasaki H, et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell. 2010;7:708\u201317.","journal-title":"Cell Stem Cell"},{"key":"2705_CR35","doi-asserted-by":"publisher","first-page":"D917","DOI":"10.1093\/nar\/gkv1101","volume":"44","author":"FO Bagger","year":"2016","unstructured":"Bagger FO, Sasivarevic D, Sohi SH, Laursen LG, Pundhir S, S\u00f8nderby CK, et al. BloodSpot: a database of gene expression profiles and transcriptional programs for healthy and malignant haematopoiesis. Nucleic Acids Res. 2016;44:D917\u201324.","journal-title":"Nucleic Acids Res"},{"key":"2705_CR36","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"2705_CR37","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.3109\/10428194.2013.867486","volume":"55","author":"PY Huang","year":"2014","unstructured":"Huang PY, Best OG, Almazi JG, Belov L, Davis ZA, Majid A, et al. Cell surface phenotype profiles distinguish stable and progressive chronic lymphocytic leukemia. Leuk Lymphoma. 2014;55:2085\u201392.","journal-title":"Leuk Lymphoma"},{"key":"2705_CR38","first-page":"1","volume":"15","author":"YE Kim","year":"2024","unstructured":"Kim YE, Calderon AA, Favaro P, Glass DR, Tsai AG, Ho D, et al. Terminal deoxynucleotidyl transferase and CD84 identify human multi-potent lymphoid progenitors. Nat Commun. 2024;15:1\u201315.","journal-title":"Nat Commun"},{"key":"2705_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/25785826.2019.1698261","volume":"43","author":"M Ando","year":"2020","unstructured":"Ando M, Ito M, Srirat T, Kondo T, Yoshimura A. Memory T cell, exhaustion, and tumor immunity. Immunol Med. 2020;43:1\u20139.","journal-title":"Immunol Med"},{"key":"2705_CR40","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.thromres.2022.10.011","volume":"220","author":"H Owji","year":"2022","unstructured":"Owji H, Negahdaripour M. The homophilic CD84 receptor is upregulated on platelets in COVID-19 and sepsis. Thromb Res. 2022;220:121\u20134.","journal-title":"Thromb Res"},{"key":"2705_CR41","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1158\/2643-3230.BCD-23-0202","volume":"5","author":"C Restelli","year":"2024","unstructured":"Restelli C, Ruella M, Paruzzo L, Tarella C, Pelicci PG, Colombo E. Recent advances in immune-based therapies for acute myeloid leukemia. Blood Cancer Discov. 2024;5:234\u201348.","journal-title":"Blood Cancer Discov"},{"key":"2705_CR42","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1182\/blood-2023-179667","volume":"142","author":"NN Shah","year":"2023","unstructured":"Shah NN, Tasian SK, Kohler ME, Hsieh EM, Baumeister SHC, Summers C, et al. CD33 CAR T-cells (CD33CART) for children and young adults with relapsed\/refractory AML: dose-escalation results from a phase I\/II multicenter trial. Blood. 2023;142:771.","journal-title":"Blood"},{"key":"2705_CR43","doi-asserted-by":"publisher","first-page":"10313","DOI":"10.1182\/blood-2022-169142","volume":"140","author":"DA Sallman","year":"2022","unstructured":"Sallman DA, Elmariah H, Sweet K, Mishra A, Cox CA, Chakaith M, et al. Phase 1\/1b safety study of Prgn-3006 Ultracar-T in patients with relapsed or refractory CD33-positive acute myeloid leukemia and higher risk myelodysplastic syndromes. Blood. 2022;140:10313\u20135.","journal-title":"Blood"},{"key":"2705_CR44","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1038\/s41375-022-01703-0","volume":"36","author":"H Zhang","year":"2022","unstructured":"Zhang H, Bu C, Peng Z, Li G, Zhou Z, Ding W, et al. Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis. Leukemia. 2022;36:2596\u2013604.","journal-title":"Leukemia"},{"key":"2705_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-022-01308-1","volume":"15","author":"X Jin","year":"2022","unstructured":"Jin X, Zhang M, Sun R, Lyu H, Xiao X, Zhang X, et al. First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed\/refractory acute myeloid leukemia. J Hematol Oncol. 2022;15:1\u20135.","journal-title":"J Hematol Oncol"},{"key":"2705_CR46","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1182\/blood-2021-147667","volume":"138","author":"J Yang","year":"2021","unstructured":"Yang J, Zhang X, Liu Y, Yang X, Wang H, Wang L, et al. High effectiveness and safety of anti-CD7 CAR T-cell therapy in treating relapsed or refractory (R\/R) T-cell acute lymphoblastic leukemia (T-ALL). Blood. 2021;138:473.","journal-title":"Blood"},{"key":"2705_CR47","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1200\/JCO.21.00389","volume":"39","author":"J Pan","year":"2021","unstructured":"Pan J, Tan Y, Wang G, Deng B, Ling Z, Song W, et al. Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial. J Clin Oncol. 2021;39:3340\u201351.","journal-title":"J Clin Oncol"},{"key":"2705_CR48","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","volume":"130","author":"D Gomes-Silva","year":"2017","unstructured":"Gomes-Silva D, Srinivasan M, Sharma S, Lee CM, Wagner DL, Davis TH, et al. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood. 2017;130:285\u201396.","journal-title":"Blood"},{"key":"2705_CR49","doi-asserted-by":"publisher","first-page":"e3515785","DOI":"10.1097\/01.HS9.0000967376.35157.85","volume":"7","author":"J Pan","year":"2023","unstructured":"Pan J, Tan Y, Deng B, Ling Z, Xu J, Duan J, et al. S116: Donor-derived CD5 CAR T cells for T-cell acute lymphoblastic leukemia. HemaSphere. 2023;7:e3515785.","journal-title":"HemaSphere"},{"key":"2705_CR50","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1038\/leu.2017.8","volume":"31","author":"KH Chen","year":"2017","unstructured":"Chen KH, Wada M, Pinz KG, Liu H, Lin KW, Jares A, et al. Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor. Leukemia. 2017;31:2151\u201360.","journal-title":"Leukemia"},{"key":"2705_CR51","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa2300709","volume":"389","author":"R Chiesa","year":"2023","unstructured":"Chiesa R, Georgiadis C, Syed F, Zhan H, Etuk A, Gkazi SA, et al. Base-edited CAR7 T cells for relapsed t-cell acute lymphoblastic leukemia. N Engl J Med. 2023;389:899\u2013910.","journal-title":"N Engl J Med"},{"key":"2705_CR52","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1182\/bloodadvances.2017009928","volume":"1","author":"YT Png","year":"2017","unstructured":"Png YT, Vinanica N, Kamiya T, Shimasaki N, Coustan-Smith E, Campana D. Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies. Blood Adv. 2017;1:2348\u201360.","journal-title":"Blood Adv"},{"key":"2705_CR53","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ymthe.2022.09.003","volume":"31","author":"N Watanabe","year":"2023","unstructured":"Watanabe N, Mo F, Zheng R, Ma R, Bray VC, van Leeuwen DG, et al. Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies. Mol Ther. 2023;31:24\u201334.","journal-title":"Mol Ther"},{"key":"2705_CR54","first-page":"321","volume":"140","author":"P Lu","year":"2022","unstructured":"Lu P, Liu Y, Yang J, Zhang X, Yang X, Wang H, et al. Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: first-in-human phase 1 clinical trial. Blood. 2022;140:321\u201334.","journal-title":"Blood"},{"key":"2705_CR55","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1182\/blood.2021015020","volume":"140","author":"A Freiwan","year":"2022","unstructured":"Freiwan A, Zoine JT, Crawford JC, Vaidya A, Schattgen SA, Myers JA, et al. Engineering naturally occurring CD7\u2212 T cells for the immunotherapy of hematological malignancies. Blood. 2022;140:2684\u201396.","journal-title":"Blood"},{"key":"2705_CR56","doi-asserted-by":"publisher","first-page":"10247","DOI":"10.1182\/blood-2022-166790","volume":"140","author":"M Pigazzi","year":"2022","unstructured":"Pigazzi M, Marini O, Porc\u00f9 E, Faggin G, Varotto E, Rizzardi P, et al. Preclinical development of a CAR-T cell approach targeting the CD84 antigen associated to pediatric acute myeloid leukemia. Blood. 2022;140:10247\u20138.","journal-title":"Blood"},{"key":"2705_CR57","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1182\/blood.2020009192","volume":"138","author":"H Jetani","year":"2021","unstructured":"Jetani H, Navarro-Bail\u00f3n A, Maucher M, Frenz S, Verbruggen C, Yeguas A, et al. Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia. Blood. 2021;138:1830\u201342.","journal-title":"Blood"},{"key":"2705_CR58","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.exphem.2008.03.015","volume":"36","author":"J Sintes","year":"2008","unstructured":"Sintes J, Romero X, Marin P, Terhorst C, Engel P. Differential expression of CD150 (SLAM) family receptors by human hematopoietic stem and progenitor cells. Exp Hematol. 2008;36:1199\u2013204.","journal-title":"Exp Hematol"},{"key":"2705_CR59","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/S0301-472X(03)00187-5","volume":"31","author":"M Zaiss","year":"2003","unstructured":"Zaiss M, Hirtreiter C, Rehli M, Rehm A, Kunz-Schughart LA, Andreesen R, et al. CD84 expression on human hematopoietic progenitor cells. Exp Hematol. 2003;31:798\u2013805.","journal-title":"Exp Hematol"},{"key":"2705_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2020.00697","volume":"10","author":"S Mardiana","year":"2020","unstructured":"Mardiana S, Gill S. CAR T cells for acute myeloid leukemia: state of the art and future directions. Front Oncol. 2020;10:1\u201312.","journal-title":"Front Oncol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02705-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02705-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02705-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T08:02:46Z","timestamp":1767772966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02705-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":60,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["2705"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02705-4","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"assertion":[{"value":"18 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PM is a cofounder of OneChain ImmunoTx, a spin-off company unrelated to this work. LP, MAU, SP, and NKG are employees of Gyala Therapeutics S.L., NKG is partially employed by Gyala Therapeutics S.L., a spin-off company of the Hospital Cl\u00ednic of Barcelona related to this work. CS is the CEO of Gyala Therapeutics S.L., a spin-off company related to this work. LP, CS, MJ, and NKG declare to be co-inventors in the patent of PCT\/EP2023\/050194. MJ declares Research Funding from Gyala Therapeutics S.L.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations, including the Declaration of Helsinki. Approval for the use of human samples was obtained from the Clinical Research Ethics Committee of Hospital Cl\u00ednic of Barcelona, under protocol numbers HCB\/2021\/0977 and HCB\/2016\/0045. Informed consent was obtained from all participants or their legal guardians prior to sample collection (reference code R121004-094). Approval for experiments involving animals was obtained from the Animal Experimentation Ethics Committee of Generalitat de Catalunya, under protocol number 11577.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}